Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899000 · ClinicalTrials.gov registry record · Phase 4
A Treatment for Severe Inflammatory Acne Subjects
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 186
- Enrollment target
- 1
- Study location
NCT02899000 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 186 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02899000, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 186 participants
- Enrollment target
- 1
- Study location
Study Summary
Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
Conditions Studied
Interventions
- DRUG Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
- DRUG Oral doxycycline hyclate
Study Locations (1)
Texas
- Galderma Laboratories, LP - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2016-07-29 |
| Est. Completion | 2017-06-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899000
The ClinicalTrials.gov registry entry for NCT02899000 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (32% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel is the first listed.
NCT02899000 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02899000 about?
NCT02899000 is a clinical study titled "A Treatment for Severe Inflammatory Acne Subjects". Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.
What is the current status of trial NCT02899000?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 186 participants. The study started on 2016-07-29. Estimated completion is 2017-06-27.
What conditions does trial NCT02899000 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02899000?
The interventions under investigation include: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (DRUG), Oral doxycycline hyclate (DRUG).
Who is sponsoring clinical trial NCT02899000?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899000 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.